An observational study in Melanoma, sponsored by Vitaccess Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.
Sponsored by Vitaccess Ltd · Observational
Among 269 studies in Melanoma with a site in United Kingdom — 31 open to participants now, 74 under way, 24 of them phase 3. Melanoma · United Kingdom.
Among the 269 studies in Melanoma with a site in United Kingdom, this one is the 15th largest by enrollment of the 41 observational ones that give a count, is one of 17 that started in 2017, is one of 41 observational ones, and was the 144th registered.
3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.
Browse Melanoma studies →31 of the 269 studies in Melanoma with a site in United Kingdom are open now. Recruiting first, the newest first:
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+
Mitra Bio · Sites in United Kingdom, Belgium, Germany and 1 more country
Ages 18+
IDEAYA Biosciences · Sites in United Kingdom, United States, Australia and 18 more countries
Ages 18+
Cancer Research UK · Sites in United Kingdom
Melanoma Institute Australia · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
269 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 108 · Phase 3 80
First in 1989; this study’s year is marked. 17 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 819 is above the median of 187 across 488 observational studies indexed under Melanoma.
Median enrollment 183 across the 226 interventional studies, 400 across the 41 observational. Of the 171 that completed or were terminated, 96 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 269 have an industry lead sponsor. The 10 most frequent:
Vitaccess Ltd is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Vitaccess Ltd has 1 study filed under Melanoma — fewer than ten, so there is no comparison to draw.
15 of the studies in Melanoma with a site in United Kingdom that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 15 to your calendar (.ics) → With an account.
Among the 269 studies in Melanoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An observational, non-interventional registry study to collect real-world data from people living with melanoma and its treatment, which will be available to researchers to further the knowledge of melanoma and improve patient care.
The registry uses Vitaccess' digital real-world evidence platform, and has been developed in collaboration with the patient advocacy group Melanoma UK.
Eligible participants install a study app on their smartphone or tablet. Researchers access aggregated, anonymised data via a cloud-based research portal. The platform provides benefits to participants, which it is hoped will encourage persistence with data submission; these include options to upload electronic documents such as scans, and access an online melanoma community.
The aggregated data are available in close to real time via "dashboards" and can be analysed according to a number of pre-set criteria (e.g. disease stage, age, geographic location).
State-of-the-art technologies and security policies are used in the platform to ensure industry-standard data storage and privacy for all users. Participants' personally identifiable information will remain confidential at all times, and researchers will not be able to identify individuals.
Adults (age ≥18 years) with melanoma of any stage, who are resident in the UK, with NHS or CHI number, current or previous diagnosis of melanoma, willing to use their own smartphone or tablet.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Health-Related Quality of Life (HRQL), general
EQ-5D-5L
Time frame: Monthly throughout 4 year study duration
Health-Related Quality of Life (HRQL), oncology
QLQ-C30
Time frame: Monthly throughout 4 year study duration
Health-Related Quality of Life (HRQL), symptoms
PRO-CTCAE
Time frame: Monthly throughout 4 year study duration
Plan to share: No — Aggregated data research dashboards will be available via industry subscriptions or free academic access.
Ran from Oct 2017 to primary completion in Dec 2021, 49 months.
Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's 49 months is above that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.